Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04738734 · ClinicalTrials.gov registry record · NA

CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts

A NA study, sponsored by Pulse Biosciences.

Completed
Registry status
NA
Development phase
150
Enrollment target

NCT04738734: Completed NA study, sponsored by Pulse Biosciences.

NCT04738734 is a NA study that has completed, run by Pulse Biosciences. The registered enrollment target is 150 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04738734, a NA study, has completed, sponsored by Pulse Biosciences.

COMPLETED
Registry status
NA
Development phase
150 participants
Enrollment target

Study Summary

This prospective, multicenter, single-blinded, randomized comparison study is designed to compare the safety and effectiveness of the CellFX System to Cryosurgery for the clearance of cutaneous non-genital common warts on all areas of the body excluding the scalp, nose, within the orbital region of the face, plantar or periungual area in healthy adult subjects.

Primary Outcome

The primary effectiveness endpoint is the percentage of warts resolved or cleared as assessed "live" by the blinded site investigator at 30 days after the last treatment with CellFX or Cryosurgical Procedure.

Interventions

  • DEVICE CellFX System Device
  • DEVICE Cryosurgery Liquid Nitrogen Sprayer

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2021-02-16
Est. Completion 2022-09-25
Phase NA
Pulse Biosciences

10 total trials

What the finished NCT04738734 record still lists

NCT04738734 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 2 interventions - of which CellFX System Device is the first listed.

NCT04738734 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04738734 about?

NCT04738734 is a clinical study titled "CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts". This prospective, multicenter, single-blinded, randomized comparison study is designed to compare the safety and effectiveness of the CellFX System to Cryosurgery for the clearance of cutaneous non-genital common warts on all areas of the body excluding the scalp, nose, within the orbital region of ...

What is the current status of trial NCT04738734?

This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2021-02-16. Estimated completion is 2022-09-25.

What interventions are being tested in trial NCT04738734?

The interventions under investigation include: CellFX System Device (DEVICE), Cryosurgery Liquid Nitrogen Sprayer (DEVICE).

Who is sponsoring clinical trial NCT04738734?

This trial is sponsored by Pulse Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04738734's enrollment target sits among peer trials

150 661st of 2000 higher than 1,299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04738734, the US trial registry maintained by the National Library of Medicine. NCT04738734 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.